July 2026's Value Stock Selections For Estimated Market Opportunities

Over the last 7 days, the United States market has experienced a 1.4% decline, yet it remains up by 17% over the past year with earnings projected to grow by 18% annually. In this environment, identifying undervalued stocks that have strong fundamentals can offer potential opportunities for investors seeking value in a fluctuating market.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name	Current Price	Fair Value (Est)	Discount (Est)
York Space Systems (YSS)	$17.42	$34.29	49.2%
VSE (VSEC)	$194.60	$382.65	49.1%
Symbotic (SYM)	$40.83	$80.29	49.1%
Ouster (OUST)	$34.77	$68.57	49.3%
Lazard (LAZ)	$42.14	$83.05	49.3%
ConnectOne Bancorp (CNOB)	$33.46	$65.56	49%
Capri Holdings (CPRI)	$15.94	$31.24	49%
Boeing (BA)	$209.48	$414.35	49.4%
Beacon Financial (BBT)	$30.49	$59.72	48.9%
American Healthcare REIT (AHR)	$56.66	$111.43	49.2%

Click here to see the full list of 151 stocks from our Undervalued US Stocks Based On Cash Flows screener.

We're going to check out a few of the best picks from our screener tool.

Gloo Holdings (GLOO)

Overview: Gloo Holdings, Inc. designs and develops a vertical technology platform for the faith and flourishing ecosystem, with a market cap of $268.50 million.

Operations: The company generates revenue of $123.89 million from its Gloo Segment, which focuses on its vertical technology platform within the faith and flourishing ecosystem.

Estimated Discount To Fair Value: 44%

Gloo Holdings is trading at $3.4, significantly below its estimated future cash flow value of $6.07, indicating it might be undervalued based on cash flows. Recent revenue growth of 310% and a forecasted annual profit growth rate of 105.77% highlight strong operational momentum despite a net loss reduction to $16.82 million in Q1 2026. The company raised its fiscal year revenue guidance to $195 million, signaling confidence in continued expansion amidst recent equity offerings totaling $22.75 million.

• In light of our recent growth report, it seems possible that Gloo Holdings' financial performance will exceed current levels.
• Unlock comprehensive insights into our analysis of Gloo Holdings stock in this financial health report.

Repligen (RGEN)

Overview: Repligen Corporation is a life sciences company that develops and commercializes bioprocessing technologies and systems globally, with a market cap of $8.31 billion.

Operations: The company generates revenue primarily through its Medical Products segment, which accounted for $763.34 million.

Estimated Discount To Fair Value: 11.9%

Repligen is trading at US$145.49, below its estimated future cash flow value of US$165.17, suggesting potential undervaluation. Despite being dropped from multiple Russell Growth Benchmarks in June 2026, Repligen's earnings are forecast to grow significantly at 30.5% annually over the next three years, outpacing the broader US market. Recent Q1 results showed revenue growth to US$194.26 million and net income improvement to US$8.33 million, reinforcing its strong financial position amidst insider selling concerns.

• Our comprehensive growth report raises the possibility that Repligen is poised for substantial financial growth.
• Click here and access our complete balance sheet health report to understand the dynamics of Repligen.

Dynatrace (DT)

Overview: Dynatrace, Inc. specializes in enhancing observability for digital businesses across various global regions, with a market cap of approximately $12.89 billion.

Operations: The company generates revenue primarily from its Internet Software & Services segment, amounting to $2.02 billion.

Estimated Discount To Fair Value: 30.9%

Dynatrace is trading at US$44.71, below its estimated future cash flow value of US$64.74, indicating it may be undervalued based on cash flows. Despite a decline in profit margins from 28.5% to 8.1%, earnings are forecast to grow significantly at 24.1% annually over the next three years, surpassing the broader US market's growth rate. Recent index additions and strategic board appointments could enhance investor confidence alongside ongoing FedRAMP High authorization pursuits for government sector expansion.

• The analysis detailed in our Dynatrace growth report hints at robust future financial performance.
• Take a closer look at Dynatrace's balance sheet health here in our report.

Key Takeaways

• Explore the 151 names from our Undervalued US Stocks Based On Cash Flows screener here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com